Injection Pen Market Grows at a Steady CAGR of 7.67%

Introduction

Straits Research released its highly anticipated report, “Injection Pen Market Size & Outlook, 2026-2034.” According to the study, the global injection pen market size is valued at USD 44.21 billion in 2025 and is projected to expand to USD 85.68 billion by 2034, registering a compound annual growth rate (CAGR) of 7.67%.

Market Dynamics

The market growth is primarily driven by the rising prevalence of chronic diseases, particularly diabetes and obesity, which continue to accelerate the adoption of injection pens for safe, precise, and convenient drug delivery. For instance, in 2025, the World Health Organization (WHO) reported that over 540 million adults globally are living with diabetes, many requiring long-term injectable therapies such as insulin or GLP-1 agonists. Such data underscore the expanding need for efficient and user-friendly injection pens. However, stringent regulatory approval processes and high manufacturing costs limit market access for smaller companies. For example, in Europe, compliance with the Medical Device Regulation (MDR) increases time to market and development expenses for new pen technologies. Despite these challenges, the market presents substantial opportunities, particularly through localized production and strategic partnerships between pharmaceutical and device manufacturers. For instance, in April 2025, Novo Nordisk announced a USD 1.09 billion investment in Brazil to expand local production of GLP-1 injection pens such as Ozempic and Wegovy, reflecting the growing regional capacity and demand for advanced delivery systems. Such developments highlight innovation, manufacturing localization, and public health initiatives that are collectively propelling the global injection pen market forward.

Market Highlights

• Type: The Disposable segment is anticipated to grow at the fastest CAGR of 8.42% during the forecast timeframe.
• Therapy: The Diabetes segment dominated the market in 2025 with a revenue share of 48.94%.
• End-User: The Home care segment is estimated to register the fastest CAGR (8.67%), fuelled by the increasing preference for self-administration of medications, growing adoption of user-friendly injection devices, and the rising prevalence of chronic conditions requiring long-term injectable therapies.
• Regional Insights: North America dominates with over 46.24% share, due to well-established healthcare infrastructure and advanced diagnostic equipment.

Competitive Players

1. Novo Nordisk A/S
2. Eli Lilly and Company
3. Sanofi
4. Ypsomed Holding
5. Becton, Dickinson and Company
6. Merck KGaA
7. AstraZeneca plc
8. Owen Mumford Ltd
9. Haselmeier GmbH
10. Sun Pharma
11. Pfizer Inc.
12. Biocon
13. Lupin Ltd
14. Novartis
15. Boehringer Ingelheim
16. Medtronic
17. Gerresheimer
18. SHL Medical
19. Nemera
20. Stevanato Group
21. Others

Recent Developments

Segmentation

1. By type (2026-2034)
   1. Disposable
   2. Reusable
2. By Therapy (2026-2034)
   1. Diabetes
   2. Growth Hormone
   3. Osteoporosis
   4. Fertility
   5. Obesity
   6. Others
3. By End user (2026-2034)
   1. Home care
   2. Hospitals and Clinics
   3. Others